Firm Moves Closer To Brain-Imaging Test for ADHD

By Darcia Harris Bowman

A Boston company is nearing the final phase of testing a diagnostic drug that could offer health-care providers a long-awaited medical test for attention deficit hyperactivity disorder.

Boston Life Sciences Inc. announced this month that its product Altropane was successful in identifying adults who had been clinically diagnosed with long- standing ADHD by mapping the level of certain chemicals in their brain.

ADHD is the most commonly diagnosed behavioral disorder in American children, affecting an estimated 2 million school-age youngsters, according to the National Institutes of Health. Characterized by hyperactivity, short attention spans, and impulsivity, the condition often interferes...

This article is available to subscribers only.

To keep reading this article and more, subscribe now or purchase this article.

Already have an account? Please login.

Subscribe to Education Week and Save

Get a full year and save up to 45%!

Premium Online + Print

37 issues + Online Access
$89

You Save 45%

SUBSCRIBE NOW

(See details.)

Premium Online

12 Months Online Access
$74

You Save 38%

SUBSCRIBE NOW

(See details.)

Most Popular Stories

Viewed

Emailed

Recommended

Commented

Sponsored Whitepapers

• E-Policy Essentials for Schools, Write a Definitive Acceptable Use Policy

• Math Intervention - From Best Practice to Next Practice

• Motivation & Personalization: Middle School Math

• Teaching Self-Regulation Skills to Close the Income-Based Achievement Gap

• Can response systems improve learning outcomes?

• Unique Challenges Facing K-12 IT Professionals

• 10 Steps for Migrating Curriculum to Common Core

• The Educational Promise of Social Media

• Broad Knowledge Drives Literacy

• Using Collaboration to Impact Teaching & Learning

• Data Systems That Help Schools Make a Difference

• Great Books Programs Fit the CCSS

MORE EDUCATION JOBS >>
Post a Job >>